RxDoctor Payments Data

Gavriil Khaimov, DPM

Foot & Ankle Surgery · Fort Lee, NJNPI 1669483426

Payments from drug & device makers

$10,903in general payments, 2019–2025

Across 139 payments — averaging $78.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$6K
  • Osteomed LLC$3K
  • Treace Medical Concepts, Inc.$714
  • Trilliant Surgical LLC.$329
  • Acumed LLC$193
  • Royal Biologics, Inc.$135
  • plus $354 from 12 others

What the payments were for

  • Speaking & faculty fees$3,25030%
  • Food & beverage$7,65370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,903 in reported general payments places this provider in the 85th percentile of 542 foot & ankle surgery providers in New Jersey.

See all foot & ankle surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$226,280
Medicare patients
590
Services billed
2,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole791$1,168,019
Diclofenac Potassium420$747,393
ErtaczoSertaconazole Nitrate205$309,643
Diflorasone Diacetate438$248,149
Oxiconazole Nitrate480$169,438
Halcinonide118$127,737
Amcinonide68$111,158
Diclofenac Epolamine140$76,115
Doxepin Hcl79$72,962
Hydrocortisone Butyrate78$30,257
Diclofenac Sodium93$29,225
Halobetasol Propionate55$5,836
Ketoconazole125$5,554
ZtlidoLidocaine14$5,143
Naftifine Hcl14$4,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$14$1,168,019791 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 542 foot & ankle surgery providers in New Jersey.

Other foot & ankle surgery in Fort Lee

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →